Patent application number | Description | Published |
20120125352 | Tobacco Curing Method - A method of curing tobacco comprises drying a harvested tobacco plant in a controlled environment for a time sufficient to substantially prevent the formation of at least one nitrosamine. The tobacco is first subjected to the controlled environment while at least a majority of the tobacco is in a green state. The resulting cured tobacco usually has tobacco-specific nitrosamine (TSNA) levels which are undetectable and are similar to levels found in freshly harvested, green tobacco. | 05-24-2012 |
20120196899 | METHODS AND PRODUCTS FOR TREATING INFLAMMATION - Pharmaceutical compositions comprising an isolated form of a compound of Formula IB (e.g., R-(+)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams. | 08-02-2012 |
20120245202 | METHODS AND PRODUCTS FOR TREATING INFLAMMATION - Pharmaceutical compositions comprising an isolated form of a compound of Formula I or IA (e.g., anatabine or S-(−)-anatabine) or a salt thereof can be used to treat disorders comprising an inflammatory component, including chronic, low-level inflammation. Compounds of Formula I also can be provided, for example, in other vehicles such as beverage products and consumer products such as lotions and creams. | 09-27-2012 |
20120325228 | ALKALOID COMPOSITION FOR E-CIGARETTE - An alkaloid composition for an e-cigarette contains a solvent and at least about 25 wt. % anatabine based on the total alkaloid weight of the composition. The alkaloid composition may be contained in a refilling cartridge for an e-cigarette, or in a container as part of a kit for refilling an e-cigarette. The alkaloid compositions disclosed herein feature a balanced form of alkaloids to provide an attractive alternative to smoking tobacco, in which nicotine makes up about 90 wt. % of the total alkaloid content. The alkaloid compositions are characterized by a significant quantity of anatabine, which has lower toxicity than other alkaloids such as nicotine. The alkaloid compositions enable individuals to experience the pleasure-enhancing attributes of conventional cigarette smoking, while avoiding exposure to combusted materials and other potentially hazardous components present in tobacco. | 12-27-2012 |
20130048001 | Anatabine-Enriched Tobacco Products - A tobacco product contains tobacco material enriched with anatabine or a salt or derivative thereof. In some aspects, the tobacco material has very low levels of tobacco specific nitrosamines (TSNA), such as having a collective content of N′-nitrosonornicotine (NNN), 4-(N-nitrosomethylamino)-1-(3-pyridyl)-1-butanone (NNK), N′-nitrosoanatabine (NAT) and N′-nitrosoanabasine (NAB) which is about 0.3 μg/g or less. The tobacco product may be a smoking product, such as cigarettes, cigars, or pipe tobacco; or a smokeless product, such as chewing tobacco, snuff, snus, tobacco-containing gum or lozenges, or a dissolvable powdered tobacco-based smokeless product. | 02-28-2013 |
20130053355 | PRODUCTS FOR ANTI-INFLAMMATION SUPPORT - This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support. | 02-28-2013 |
20130195780 | Skin Care Products Contianing Anatabine Or Derivative Thereof - A skin care product includes a compound of Formula I, IA, or IB (e.g., anatabine), or a salt thereof, and a suitable cosmetic or pharmaceutical vehicle. In some aspects, the skin care product is a paste, cream, lotion, gel, moisturizer, cleanser, or sunscreen. In some embodiments, the skin care product is applied topically to reduce inflammation, redness, and/or irritation, and/or to improve the appearance of the skin. In other embodiments, the skin care product is applied topically to treat an autoimmune and/or dermatological condition such as acne, psoriasis, and/or rosacea. | 08-01-2013 |
20130298921 | INHALER FOR SMOKING CESSATION - An alkaloid composition for an inhaler contains a solvent and at least about 25 wt. % anatabine based on the total alkaloid weight of the composition. The alkaloid composition may be contained in a refilling cartridge for an inhaler, or in a container as part of a kit for refilling an inhaler. The alkaloid compositions disclosed herein feature a balanced form of alkaloids to provide an attractive alternative to smoking tobacco, in which nicotine makes up about 90 wt. % of the total alkaloid content. The alkaloid compositions are characterized by a significant quantity of anatabine, which has lower toxicity than other alkaloids such as nicotine. The alkaloid compositions enable individuals to experience the pleasure-enhancing attributes of conventional cigarette smoking, while avoiding exposure to combusted materials and other potentially hazardous components present in tobacco. | 11-14-2013 |
20140057949 | Beverage Products - This disclosure provides beverage products comprising a compound of Formula I, such as anatabine, suitable for human consumption. | 02-27-2014 |
20140206656 | METHODS OF PROVIDING ANTI-INFLAMMATION SUPPORT - This disclosure provides products, including pharmaceutical compositions and dietary supplements, which are useful for anti-inflammatory support. | 07-24-2014 |